MB,ChB. Research Fellow at The Royal Marsden Hospital. London. Melanoma, Thoracic Oncology, Immunotherapy, Education, Sandwichesš³šæš“ó §ó ¢ó ³ó £ó “ó æ
Joined June 2009
- Tweets409
- Following614
- Followers157
- Likes378
Someone who trained as a doctor, goes into a non-clinical role & starts consulting for McKinsey probably never actually liked real clinical work
AI healthcare needs to be shaped by real patients & doctors, not by āleadersā who stopped doing clinical work half a career ago
In the NHS of the future, you may never need a doctor or nurse, says NHS England chair Penny Dash. Smartphone care, AI and robotics will transform the medical system, and automate entire patient pathways she believes: thetimes.com/article/d408694ā¦
Sad to learn of the death of Prof Richard Scolyer. A true giant of the field of melanoma, and a brave advocate for cancer research and for those living with cancer
theguardian.com/society/2026ā¦
I respect DCs passion on this issue, but I think his drive for change is focused on the wrong question
Any screening programme must ask āhow good is the test?ā
False-positives lead to unneccessary medical intervention. False-negatives give unwarranted reassurance
1/2
Todayās decision from the Health Secretary on prostate cancer screening is a missed opportunity - too timid, too slow, and lacking the bold ambition that we so desperately wanted to see.
As I set out last week, I fundamentally disagree with the National Screening Committeeās advice on a future screening programme for prostate cancer, which is far too narrow. I strongly believe that if we are really to get on top of prostate cancer - the most common cancer in British men - then a proper, targeted screening programme for all those at higher risk is neededā¦ and needed now.
I welcome expanded provision of focal therapy, which I benefited from last year with my own cancer; this must be an urgent priority to make available across the NHS. And the recognition that more work is needed to screen at risk groups, such as black men, is important.
But this was an opportunity for bold, decisive, life-saving action - action that would help save the heartache of too many families losing a loved-one to this disease. That, sadly, has been missed. We will continue the campaign to urge the Government to go further, faster and put in place a progressive policy that includes a proper screening programme for the most at-risk men.
key is that current PSA blood tests are helpful in high risk men, but less helpful or unhelpful where risk is low (but not zero)
I suggest a call to action to develop better screening techniques that are more sensitive and more specific for prostate cancer. @David_Cameron
2/2
Latest update on #CROWN shows mPFS for lorlatinib still not reached at 7 years. Benefit across all subgroups including brain mets.
This should push us to examine the paradigm: at what point does āincurable cancerā become āchronic diseaseā?
#ASCO26 #NSCLC #ALK #LCSM
Impressive improvement in PFS. Exciting option to bring targeted therapy forward into first line, delaying use of chemo.
OS data still immature and rates of Gā„3 tox high for Sunvoz, exceeding that of Chemo. Much to considerā¦
#ASCO26 #LCSM
Presented at #ASCO26:
In NSCLC with šššš exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. Full phase 3 WU-KONG28 trial results: nej.md/4fQWMwa
@ASCO
ALT A Kaplan-Meier graph from the Original Article "First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations," which is being published in conjunction with a presentation at ASCO. The graph compares progression-free survival rates between sunvozertinib and chemotherapy for NSCLC with EGFR Exon 20 insertion mutations. Statistical details and a logo for the New England Journal of Medicine are present at the bottom.
This article from @JamesTGallagher @BBCNews gives a really clear lay-language summary of the pros and cons of #prostatecancer #screening. Well worth a read for blokes over 50
Yes there is a test. The test isnāt perfect. Risks outweigh the gains for most
bbc.co.uk/news/articles/cn0pā¦
Recommendations from UK National Screening Committee on #ProstateCancer are balanced and evidence based
No test is perfect and screening can do more harm than good
Appreciate some are disappointed. The way forward is to develop better screening tests
view-health-screening-recommā¦
Itās #ASCO26 week! @ASCO
Top picks that Iām excited about are:
1) HARMONi-6
OS results of Ivonescimab + chemo vs tislelizumab+chemo Iām 1Ā° setting for advanced squamous NSCLC.
Ivo data soo far has been promising, this could be a new SoCš«
#lcsm #NSCLC @OncoAlert
4) DeLLphi-304
Intracranial efficacy of tarlatimab vs chemo in 2Ā° setting for SCLC
Critically relevant clinical issue in an area of need and uncertainty š«
3) TRITON
Phase 2b Treme(CTLA-4) + Durva + Chemo VS Pembro + chemo 1st line in NSCLC with KRAS, STK11 or KEAP1 mutation
many recent small steps forward in the mission to produce a meaningful KRAS targeted regimen. Addition of CTLA-4 is clinically and academically informative š«
2) ROSETTA Lung-02
Pumitamig vs chemo 1Ā° in NSCLC
Sticking with the PD-L1 x VEGF bispecific theme, these agents have a high chance of being the next step forward into real practice š«
#ASCO26 @OncoAlert #NSCLC #LCSM
Hey @JeffBezos, I bought a shirt on Amazon today. Was planning to get it delivered to my home, until you threw up this left field option. I live in London UK. Never been to Luxembourg. Even for the cheap cheap price of Free, this is not super convenient @amazon
$1Trillion is enough wealth for a million people to each become a millionaire
Itās enough for 10million people to buy a small apartment
Itās enough for 20million people to get a university education
Nobody benefits from Malignant Capitalism
bbc.com/news/articles/cwyk6kā¦
